Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial

NCT03865511 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT03865511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03865511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 9, 2019
Completion date
January 31, 2025
Enrollment
150 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer